saxagliptin
Sign in to saveAlso known as BMS-477118, BMS 477118, (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile, saxagliptin anhydrous, Saxagliptin anhydrous
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 315.194677
- Has use
- medication
Show 9 more facts
- chemical formula
- C₁₈H₂₅N₃O₂
- isomeric SMILES
- C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
- canonical SMILES
- C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
- World Health Organisation international non-proprietary name
- saxagliptin
- defined daily dose
- 5
- subject has role
- dipeptidyl peptidase-4 inhibitors
- physically interacts with
- Dipeptidyl peptidase 4
- stylized name
- sAXagliptin
- Commons category
- Saxagliptin
Sources (7)
via Wikidata · CC0
~8 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Adverse effects
- Tolerability
- Pancreatitis and pancreatic cancer
- Production
- Pharmacology
- Licensing
- References
- External links
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."
Excerpted from Wikipedia’s “saxagliptin” article, available under the CC BY-SA 4.0 licence.